35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer is a dataset published in ESMO Open (2024). On theSindex it has a DataRank of 0.452, placing it in the top 41.7% of the data-sharing corpus. It has been cited 8 times, with 8 citing works in its 1-hop citation network.
Ranks in the top 42% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0.123
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 8 citers.
National Institutes of Health
Grant: P30CA008748
National Institutes of Health
Grant: 1R01CA251591001A1
National Institutes of Health
Grant: 1R01CA273224-01
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy
FWCI
2.19
Citation Percentile
0.9%
Influential Citations
2
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals